Skip to main content Accessibility help
×
Home

An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator

  • Kristina A. Coleman (a1), Vanessa Y. Xavier (a2), Trish L. Palmer (a2), James V. Meaney (a2), Libby M. Radalj (a1) and Louise M. Canny (a3)...

Abstract

Background

This meta-analysis compared the efficacy and safety of desvenlafaxine and venlafaxine at the Australian approved doses.

Methods

A systematic literature search was conducted to identify all placebo-controlled studies of desvenlafaxine and venlafaxine in the treatment of major depression. The pivotal outcome measure used to assess comparative efficacy was the mean change in Hamilton Rating Scale for Depression-17 score from baseline. Tolerability and safety were compared by an evaluation of reported adverse events. Standard and Bayesian methods were used to conduct the indirect comparisons.

Findings

Using a mixed model repeated measures analysis, the pooled weighted mean difference for the mean change in Hamilton Rating Scale for Depression-17 score from baseline was −2.81 (−3.72, −1.91; p < 0.001) for desvenlafaxine and −2.61 (−3.17, −2.05; p < 0.001) for venlafaxine. An indirect Bayesian analysis adjusted for baseline Hamilton Rating Scale for Depression-17 score showed no significant difference between the two treatments (weighted mean difference −0.27; −1.17, 0.65). A standard indirect comparison of any adverse events showed no significant difference between desvenlafaxine and venlafaxine (relative risk 1.01; 0.96, 1.06; p = 0.70 and risk difference −0.01; −0.05, 0.03; p = 0.59). Standard indirect comparisons of both nausea and drop-outs identified potential differences between treatments, with the risk difference analyses suggesting a trend in favor of desvenlafaxine (nausea: relative risk 0.97; 0.77, 1.22; p = 0.80/RD −0.07; −0.12, −0.01; p = 0.02; and drop-outs due to adverse events: RR 0.86; 0.58, 1.29; p = 0.48/RD −0.04; −0.08, 0.00; p = 0.06).

Conclusions

Based on the results of this meta-analysis, desvenlafaxine was shown to be non-inferior to venlafaxine in terms of efficacy, and has an advantage in terms of less nausea.

Copyright

Corresponding author

*Address for correspondence: James Meaney, Scientific & Regulatory Affairs Director, Pfizer Australia, 17–19 Solent Circuit, Baulkham Hills NSW 2153, Australia. Telephone: 61 2 9850 8408; Fascimile: 61 2 9023 0033.(Email Jim.Meaney@pfizer.com)

References

Hide All
1.Australian Bureau of Statistics. National Survey of Mental Health and Wellbeing: Summary of Results, 2007. ABS Cat No. 4326.0. Canberra: ABS.
2.Mant, A, Rendle, VA, Hall, WD, et al. . Making new choices about antidepressants in Australia: the long view 1975–2002. Med J Aust. 2004; 181(7 suppl.): S21S24.
3.Hickie, IB, Davenport, TA, Scott, EM, et al. . Unmet need for recognition of common mental disorders in Australian general practice. Med J Aust. 2001; 175(suppl.): S18S24.
4.Deecher, DC, Beyer, CE, Johnston, G, et al. . Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006; 318(2): 657665.
5.Preskorn, S, Patroneva, A, Silman, H, et al. . Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol. 2009; 29(1): 3943.
6.Shams, MEE, Arneth, B, Hiemke, C, et al. . CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006; 31(5): 493502.
7.Hermann, M, Hendset, M, Fosaas, K, Hjerpset, M, Refsum, H. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3,*4 or*5 allele. Eur J Clin Pharmcol. 2008; 64(5): 483487.
8.McAlpine, DE, O'Kane, DJ, Black, JL, Mrazek, DA. Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin Proc. 2007; 82(9): 10651068.
9.Septien-Velez, L, Pitrosky, B, Padmanabhan, SK, Germain, JM, Tourian, KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007; 22(6): 338347.
10.DeMartinis, NA, Yeung, PP, Entsuah, R, Manley, AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007; 68(5): 677688.
11.Lieberman, DZ, Montgomery, SA, Tourian, KA, et al. . A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol. 2008; 23(4): 188197.
12.Liebowitz, M, Manley, A, Padmanabhan, S, et al. . Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008; 24(7): 18771890.
13.Boyer, P, Montgomery, S, Lepola, U, et al. . Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008; 23(5): 243253.
14. Pristiq® (desvenlafaxine succinate) Product Information, Wyeth Australia.
15.Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
16.Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. Washington, DC: American Psychiatric Association; 1987.
17.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23(1): 5662.
18.Bucher, HC, Guyatt, GH, Griffith, LE, Walter, SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997; 50(6): 683691.
19. Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS: User Manual, Version 2.10. Medical Research Council Biostatistics Unit, Cambridge, UK, 2005.
20. Data on file, Wyeth Australia. A multicentre, randomized, double-blind, placebo-controlled study of 2 fixed doses of DVS-233 SR in adult outpatients with major depressive disorder. CSR 49148, 2004.
21.Liebowitz, MR, Yeung, PP, Entsuah, R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007; 68(11): 16631672.
22. Data on file, Wyeth Australia. A multicentre, randomized, double-blind, placebo-controlled, duloxetine-referenced, parallel-group study to evaluate the efficacy and safety of 2 fixed doses (50 mg, 100 mg) of desvenlafaxine sustained-release tablets in adult outpatients with major depressive disorder. Protocol 3151A1-335. CSR 70296, 2008.
23.Khan, A, Fabre, LF, Rudolph, R. Venlafaxine in depressed outpatients. Psychopharmacol Bull. 1991; 27(2): 141144.
24.Nemeroff, CB, Thase, ME. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed putpatients. J Psychiatr Res. 2007; 41(3–4): 351359.
25.Schatzberg, A, Roose, S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry. 2006; 14(4): 361370.
26.Rudolph, RL, Fabre, LF, Feighner, JP, et al. . A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry. 1998; 59(3): 116122.
27.Cunningham, LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry. 1997; 9(3): 157164.
28.Thase, ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry. 1997; 58(9): 393398.
29.Rudolph, RL, Feiger, AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord. 1999; 56(2–3): 171181.
30. Data on file, Wyeth Australia. Double-blind, placebo-controlled study of venlafaxine-ER and venlafaxine-OROS in outpatients with major depression. Protocol 0600C-217-US. CSR 45150, 2002.
31.Schweizer, E, Feighner, J, Mandos, LA, Rickels, K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry. 1994; 55(3): 104108.
32.Cunningham, LA, Borison, RL, Carman, JS, et al. . A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol. 1994; 14(2): 99106.
33. Data on file, Wyeth Australia. Randomized, double-blind comparison of venlafaxine (WY 45030), imipramine and placebo capsules in outpatients with major depression. Protocol 0600A-303-US. GMR 20448, 1991.
34. Data on file, Wyeth Australia. A multicentre, randomized, double-blind, placebo-controlled, parallel-group, flexible-dose study of DVS-233 SR and venlafaxine ER in adult outpatients with major depressive disorder. Protocol 3151A1-309, 2007.
35.Mendels, J, Johnston, R, Mattes, J, Riesenberg, R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull. 1993; 29(2): 169174.
36. Data on file, Wyeth Australia. A multicentre, randomized, double-blind, placebo-controlled, parallel-group, flexible-dose study of DVS-233 SR and venlafaxine ER in adult outpatients with major depressive disorder. Protocol 3151A1-317, 2007.
37. Data on file, Wyeth Australia. A double-blind, placebo-controlled, parallel-group dosage comparison study of BID and TID dosing of venlafaxine in outpatients with major depression. Protocol 0600A1-341-US. CSR 42676, 2001.
38.Khan, A, Upton, GV, Rudolph, RL, Entsuah, R, Leventer, SM. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol. 1998; 18(1): 1925.
39.Lecrubier, Y, Bourin, M, Moon, CAL, et al. . Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand. 1997; 95(6): 485493.
40.Silverstone, PH, Ravindran, A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry. 1999; 60(1): 2228.
41. Salinas E. Once-daily venlafaxine XR vs. paroxetine in outpatients with major depression. Presented at the 11th European College of Neuropsychopharmacology Congress Paris, France, October 31–November 4, 1998.
42. Data on file, Wyeth Australia. A double-blind, placebo-controlled comparative efficacy study of venlafaxine ER and sertraline in producing remission in outpatients with major depressive disorder. Protocol 0600B1-402-US. CSR 48579, 1999.
43.Troy, SM, Dilea, C, Martin, PT, et al. . Pharmacokinetics of once-daily venlafaxine extended release in healthy volunteers. Current Therapeutic Research. 1997; 58(8): 504514.
44.Deecher, DC, Beyer, CE, Johnston, G, et al. . Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006; 318(2): 657665.
45.Caraco, Y. Genes and the response to drugs. N Engl J Med. 2004; 351(27): 28672869.
46.Siddiqui, O, Hung, HM, O'Neill, R. MMRM vs LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat. 2009; 19(2): 227246.
47.Song, F, Altman, DG, Glenny, A-M, Deeks, JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003; 326(7387): 472.
48.Perahia, DG, Pritchett, YL, Kajdasz, DK, et al. . A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res. 2008; 42(1): 2234.
49.Lee, P, Shu, L, Xu, X, et al. . Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. Psychiatry and Clinical Neurosciences. 2007; 61(3): 295307.
50.Szegedi, A, Kohnen, R, Dienel, A, Kieser, M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ. 2005; 330(7490): 503507.
51.Kirsch, I, Deacon, BJ, Huedo-Medina, TB, et al. . Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008; 5(2): e45.

Keywords

An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator

  • Kristina A. Coleman (a1), Vanessa Y. Xavier (a2), Trish L. Palmer (a2), James V. Meaney (a2), Libby M. Radalj (a1) and Louise M. Canny (a3)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed